title: Predicting CD4 lymphocyte count <200 cells/mm(3) in an HIV type 1-infected African population.
abstract: Clinical criteria are recommended to select HIV-infected patients for initiation of antiretroviral therapy when CD4 lymphocyte testing is unavailable. We evaluated the performance characteristics of WHO staging criteria, anthropometrics, and simple laboratory measurements for predicting CD4 lymphocyte count (CD4 count) <200 cells/mm(3) among HIV-infected patients in Tanzania. A total of 202 adults, diagnosed with HIV infection through community-based testing, underwent a detailed evaluation including staging history and examination, anthropometry, complete blood count, erythrocyte sedimentation rate (ESR), and CD4 count. Univariable analysis and recursive partitioning were used to identify characteristics associated with CD4 count 200 cells/mm(3). Of 202 participants 109 (54%) had a CD4 count <200 cells/mm(3). Characteristics most strongly associated with CD4 count <200 cells/mm(3) (p-value <0.0001) were the presence of mucocutaneous manifestations (72% vs. 28%), lower total lymphocyte count (TLC) (median 1,450 vs. 2,200 cells/mm(3)), lower total white blood cell count (median 4,200 vs. 5,500 cells/mm(3)), and higher ESR (median 95 vs. 53 mm/h). In a partition tree model, TLC <1,200 cells/mm(3), ESR >or=120 mm/h, or the presence of mucocutaneous manifestations yielded a sensitivity of 0.85 and specificity of 0.63 for predicting CD4 count <200 cells/mm(3). The sensitivity of the 2006 WHO Staging system improved from 0.75 to 0.93 with inclusion of these parameters, at the expense of specificity (0.36 to 0.26). The presence of mucocutaneous manifestations, TLC <1,200 cells/mm(3), or ESR >or=120 mm/h was a strong predictor of CD4 count <200 cells/mm(3) and enhanced the sensitivity of the 2006 WHO staging criteria for identifying patients likely to benefit from antiretrovirals.
authors.affiliation: Duke University Medical Center, Durham, North Carolina, 27710., Kilimanjaro Christian Medical Centre, Moshi, Tanzania.
authors.forename: Susan C
authors.initials: SC
authors.lastname: Morpeth
authors.forename: John A
authors.initials: JA
authors.lastname: Crump
authors.forename: Humphrey J
authors.initials: HJ
authors.lastname: Shao
authors.forename: Habib O
authors.initials: HO
authors.lastname: Ramadhani
authors.forename: Peter R
authors.initials: PR
authors.lastname: Kisenge
authors.forename: Cindy A
authors.initials: CA
authors.lastname: Moylan
authors.forename: Susanna
authors.initials: S
authors.lastname: Naggie
authors.forename: L Brett
authors.initials: LB
authors.lastname: Caram
authors.forename: Keren Z
authors.initials: KZ
authors.lastname: Landman
authors.forename: Noel E
authors.initials: NE
authors.lastname: Sam
authors.forename: Dafrosa K
authors.initials: DK
authors.lastname: Itemba
authors.forename: John F
authors.initials: JF
authors.lastname: Shao
authors.forename: John A
authors.initials: JA
authors.lastname: Bartlett
authors.forename: Nathan M
authors.initials: NM
authors.lastname: Thielman
mesh_terms: D000328:Adult; D000349:Africa; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000276:immunology* / Q000821:virology; D015497:HIV-1; D006801:Humans; D018655:Lymphocyte Count; D008297:Male; D011237:Predictive Value of Tests; D012372:ROC Curve; D012680:Sensitivity and Specificity; D012871:Skin Diseases / Q000175:diagnosis; D014944:World Health Organization